Becton Dickinson to acquire Bard for $24bn

Medical technology company Becton Dickinson (BD) will acquire C R Bard, a business in the same industry, for $24 billion.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotech

Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight

21 September 2026 Judges agreed with the Oxford University spin-out that MGI Tech was likely to infringe Oxford’s patent, and banned sales of certain Cyclone devices to preserve the one-player-market status quo.

Careers

Benesch adds former McDermott IP practice head

21 September 2026 The hire brings more than three decades of experience across patent litigation, prosecution, licensing and cross-border matters, advising clients in the medical devices, automotive, manufacturing, consumer products, software and electronics sectors.

Careers

Leading European patent litigator to join Carpmaels & Ransford

18 September 2026 The new hire brings more than two decades’ experience managing complex cross-border disputes in life sciences and technology, including most recently at the Unified Patent Court.

More features

Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight

Benesch adds former McDermott IP practice head

Leading European patent litigator to join Carpmaels & Ransford

CIPA Congress: Sustainability is essential for the profession and the planet

Non-profit sues Cambrex over anticancer drug manufacturing trade secrets

Inside the deal boom: LSIPR’s five-part M&A series—all in one place

Amgen hit with lawsuit over its proposed Opdivo biosimilar

Australian biotech sues Grail over multi-cancer blood test

Becton Dickinson to acquire Bard for $24bn

More on this story

Editor's picks

Editor's picks

More features